EXciteOSA, Daytime Sleep Apnea Therapy Device, Surpasses 50,000 Patient Session Milestone
“It was easy to find 20 minutes during the day to use it and the results have paid off. My husband now sleeps better without my snoring, and so do I.”
Category: Neurostimulators
Neurostimulators
Latest
Neurostimulators
Latest
Signifier Raises $35M to Accelerate Commercialization of eXciteOSA Therapy
Proceeds of the financing will be directed towards commercialization of eXciteOSA in core target markets, continued development of proprietary digital patient and physician interface platforms, the generation of additional clinical data to reinforce the therapeutic efficacy of eXciteOSA, and progressing reimbursement.
Neurostimulators
Latest
FDA Approves Inspire Medical’s New Physician Programmer Platform
A new telemetry cable enables Bluetooth connectivity to the programmer tablet. The platform interfaces with Inspire Cloud.
ZOLL Medical Acquires Respicardia
ZOLL, which has been a significant investor in Respicardia for more than 3 years, will welcome all Respicardia employees into its workforce.
Read More
Signifier’s Daytime OSA Therapy Wins 2020 GOOD DESIGN Award
The GOOD DESIGN award is presented by The Chicago Athenaeum Museum of Architecture and Design and The European Centre for Architecture Art Design and Urban Studies.
Read More
Patient with Complete Concentric Airway Collapse Achieves Control of Sleep Apnea in Nyxoah Neurostimulator Study
Currently, patients with complete concentric collapse are contraindicated for hypoglossal nerve stimulation OSA therapies.
Read More
Tampa General Becomes One of Select Hospitals to Offer Respicardia Remedē for Central Sleep Apnea
The Respicardia remedē system is an implantable pacemaker-like battery pack that stimulates the phrenic nerve.
Read MoreFDA: Patients with Nyxoah Implant OK to Undergo MRI
This revised labeling ensures that patients who receive the Genio system and those already implanted can now undergo full-body 1.5T and 3T MRI diagnostic scans within approved parameters.
Read More
Nyxoah Partners with Vanderbilt to Develop More Neurostimulation Tech for OSA
The agreement allows Nyxoah to further develop new neurostimulation technologies for the treatment of sleep-disordered breathing conditions that were invented by Vanderbilt’s David T. Kent, MD.
Read MoreEuropean Union: Patients with Nyxoah Implant OK to Undergo MRI
‘Those who may need an MRI can benefit from Nyxoah’s innovations with no fear for themselves and their implant during the exam.’
Read More
Multidisciplinary Perspectives on OSA Treatment with Inspire for CPAP-intolerant Patients
Panelists discuss proper patient selection, preparation for device evaluation and the procedure, and post-implant adjustments.
Read More
Highmark Adds Coverage for Remedē System in Patients with Central Sleep Apnea
Highmark Blue Cross Blue Shield and its affiliates will provide coverage for the Respicardia Inc’s remedē System implantable therapy for central sleep apnea, effective immediately.
Read MoreFirst US Patient Implanted in Pivotal Trial for OSA Neurostimulator
The implantation took place at the Nose and Sinus Institute Boca Raton, Fla, and was performed by Melyssa Hancock, MD.
Read MoreFirst Patient Implanted in Pivotal Trial for Sleep Apnea Neurostimulator
The DREAM (Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea) study is a pivotal, Investigational Device Exemption trial designed to support the marketing authorization of the Genio system in the United States.
Read MoreFirst Patient Enrolls in Central Sleep Apnea Trial to Assess Alternative Transvenous Lead Location for Remedē Implant
The trial seeks to explore whether transvenous stimulation can improve airway physiology.
Read More
Remedē Shows Sustained Safety & Efficacy Through 5 Years
Highlights from the 5-year data show sustained improvements that were consistent with the published 6-, 12-, 24-, and 36-month results.
Read More
After Two Decades, 73-Year-Old Finds Sleep Apnea Therapy That Works for Him
After more than 20 years of troubled sleep, Dwight Johnson can finally sleep peacefully throughout the night.
Read MoreHumana Now Provides Coverage for Inspire Upper Airway Stimulation
Health plan provider Humana Inc will provide coverage for Inspire upper airway stimulation therapy, effective August 27.
Read More